{"id":23154,"date":"2018-06-14T15:40:22","date_gmt":"2018-06-14T19:40:22","guid":{"rendered":"https:\/\/ipo.org\/?p=23154"},"modified":"2018-07-06T15:43:10","modified_gmt":"2018-07-06T19:43:10","slug":"patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer","status":"publish","type":"post","link":"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/","title":{"rendered":"Patent Eligbility in the Life Sciences: Exergen and Praxair- and USPTO Memos on Vanda and Berkheimer"},"content":{"rendered":"<div style=\"font-weight: 400;\">\n<div>\n<p paraid=\"881699857\" paraeid=\"{8cdfd6b7-c0e4-47b6-8eca-744109a2a760}{182}\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Pity the life sciences patent prosecutor who tries to find a path through recent appellate court decisions regarding patent eligibility.\u00a0 A recent concurrence in a divided Federal Circuit decision indicated that U.S. Supreme Court decisions like\u00a0<\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Mayo\u00a0<\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>have left too much uncertainty about what is and is not patent eligible under section 101.\u00a0 Like others in the IP community, the concurrence indicated that perhaps Congress should act.\u00a0 But few experts expect a legislative fix to come quickly. That leaves both patent owners and applicants with a pressing need to assess the impact of recent significant Federal Circuit opinions, such as<\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>\u00a0<\/span><\/span><\/i><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Exergen<\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>,\u00a0<\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Vanda<\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>\u00a0and\u00a0<\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Praxair<\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>.<\/span><\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<\/div>\n<ul role=\"list\">\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"39\" aria-setsize=\"-1\" data-aria-posinset=\"1\" role=\"listitem\" data-aria-level=\"1\"><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Exergen<\/span><\/span><\/i><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>\u00a0<\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>and\u00a0<\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Vanda<\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>\u00a0have been the cause for cautious optimism for some life science companies.<\/span><\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:300,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"39\" aria-setsize=\"-1\" data-aria-posinset=\"2\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Exergen\u2019s<\/span><\/span><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>\u00a0invention, a diagnostic patent, was upheld under section 101 by the Federal Circuit, which was considered an important event post-<\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Mayo<\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>. This decision is referenced in the USPTO\u2019s\u00a0<\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Berkheimer<\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>\u00a0memo of 19 April, which takes the agency into the uncharted territory of trying to decide how much and what kind of evidence it takes to show that an invention is not \u201cwell understood, routine and conventional.\u201d<\/span><\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:300,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"39\" aria-setsize=\"-1\" data-aria-posinset=\"3\" role=\"listitem\" data-aria-level=\"1\"><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Vanda<\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>\u00a0affirmed a district court\u2019s finding that claims to a personalized method of treatment are patent eligible. In early June, the USPTO issued a new memo to examiners on\u00a0<\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Vanda<\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>. The Federal Circuit decision didn\u2019t address\u00a0<\/span><\/span><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>a number of<\/span><\/span><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>\u00a0relevant issues, however, such as whether a doctor could be a direct infringer through divided infringement.<\/span><\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:300,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"39\" aria-setsize=\"-1\" data-aria-posinset=\"3\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>The most recent of the three decisions is far more ominous for life science inventions.<span>\u00a0<\/span><\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Praxair,<span>\u00a0<\/span><\/span><\/span><\/i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>a recent appeal of an IPR decision, could result in many section 101 challenges being made in IPRs in the form of a printed matter\/obviousness challenge.<\/span><\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:300,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<\/div>\n<div style=\"font-weight: 400;\">\n<div>\n<p paraid=\"1969272791\" paraeid=\"{ab51786d-5b4a-4f1a-96cb-5a696a8303ef}{11}\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Our panel includes a life sciences expert at the USPTO, a top patent lawyer at a major pharmaceutical company, and a founding shareholder of an IP law firm who specializes in biotech.\u00a0 They will assess the cumulative impact of recent changes and delineate prosecution strategies to address them.<\/span><\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p paraid=\"2122511544\" paraeid=\"{ab51786d-5b4a-4f1a-96cb-5a696a8303ef}{17}\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Speakers:<\/span><\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<\/div>\n<ul role=\"list\">\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"39\" aria-setsize=\"-1\" data-aria-posinset=\"2\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Paul Golian,<span>\u00a0<\/span><\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Bristol-Myers Squibb Company<\/span><\/span><\/i><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:300,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"39\" aria-setsize=\"-1\" data-aria-posinset=\"3\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Ali Salimi,<span>\u00a0<\/span><\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>U.S. Patent &amp; Trademark Office<\/span><\/span><\/i><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:300,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"39\" aria-setsize=\"-1\" data-aria-posinset=\"3\" role=\"listitem\" data-aria-level=\"1\"><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Warren Woessner,<span>\u00a0<\/span><\/span><\/span><i><span xml:lang=\"EN-US\" lang=\"EN-US\"><span>Schwegman, Lundberg &amp; Woessner, P.A.<\/span><\/span><\/i><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:300,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<\/div>\n<div style=\"font-weight: 400;\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pity the life sciences patent prosecutor who tries to find  [&#8230;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-23154","post","type-post","status-publish","format-standard","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Patent Eligbility in the Life Sciences: Exergen and Praxair- and USPTO Memos on Vanda and Berkheimer - Intellectual Property Owners Association<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Patent Eligbility in the Life Sciences: Exergen and Praxair- and USPTO Memos on Vanda and Berkheimer - Intellectual Property Owners Association\" \/>\n<meta property=\"og:description\" content=\"Pity the life sciences patent prosecutor who tries to find [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"Intellectual Property Owners Association\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/IPOAssociation\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-06-14T19:40:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-07-06T19:43:10+00:00\" \/>\n<meta name=\"author\" content=\"ipoadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ipo\" \/>\n<meta name=\"twitter:site\" content=\"@ipo\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ipoadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\\\/\"},\"author\":{\"name\":\"ipoadmin\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/person\\\/8226b50acbf234bbf0f5d70f4a84ba47\"},\"headline\":\"Patent Eligbility in the Life Sciences: Exergen and Praxair- and USPTO Memos on Vanda and Berkheimer\",\"datePublished\":\"2018-06-14T19:40:22+00:00\",\"dateModified\":\"2018-07-06T19:43:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\\\/\"},\"wordCount\":371,\"publisher\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\\\/\",\"url\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\\\/\",\"name\":\"Patent Eligbility in the Life Sciences: Exergen and Praxair- and USPTO Memos on Vanda and Berkheimer - Intellectual Property Owners Association\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#website\"},\"datePublished\":\"2018-06-14T19:40:22+00:00\",\"dateModified\":\"2018-07-06T19:43:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ipo.org\\\/index.php\\\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ipo.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Patent Eligbility in the Life Sciences: Exergen and Praxair- and USPTO Memos on Vanda and Berkheimer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#website\",\"url\":\"https:\\\/\\\/ipo.org\\\/\",\"name\":\"Intellectual Property Owners Association\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ipo.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\",\"name\":\"Intellectual Property Owners Association\",\"url\":\"https:\\\/\\\/ipo.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ipo.org\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/ipo_logo.png\",\"contentUrl\":\"https:\\\/\\\/ipo.org\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/ipo_logo.png\",\"width\":570,\"height\":226,\"caption\":\"Intellectual Property Owners Association\"},\"image\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/IPOAssociation\\\/\",\"https:\\\/\\\/x.com\\\/ipo\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ipoassociation\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/person\\\/8226b50acbf234bbf0f5d70f4a84ba47\",\"name\":\"ipoadmin\",\"url\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/author\\\/ipoadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Patent Eligbility in the Life Sciences: Exergen and Praxair- and USPTO Memos on Vanda and Berkheimer - Intellectual Property Owners Association","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/","og_locale":"en_US","og_type":"article","og_title":"Patent Eligbility in the Life Sciences: Exergen and Praxair- and USPTO Memos on Vanda and Berkheimer - Intellectual Property Owners Association","og_description":"Pity the life sciences patent prosecutor who tries to find [...]","og_url":"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/","og_site_name":"Intellectual Property Owners Association","article_publisher":"https:\/\/www.facebook.com\/IPOAssociation\/","article_published_time":"2018-06-14T19:40:22+00:00","article_modified_time":"2018-07-06T19:43:10+00:00","author":"ipoadmin","twitter_card":"summary_large_image","twitter_creator":"@ipo","twitter_site":"@ipo","twitter_misc":{"Written by":"ipoadmin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/#article","isPartOf":{"@id":"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/"},"author":{"name":"ipoadmin","@id":"https:\/\/ipo.org\/#\/schema\/person\/8226b50acbf234bbf0f5d70f4a84ba47"},"headline":"Patent Eligbility in the Life Sciences: Exergen and Praxair- and USPTO Memos on Vanda and Berkheimer","datePublished":"2018-06-14T19:40:22+00:00","dateModified":"2018-07-06T19:43:10+00:00","mainEntityOfPage":{"@id":"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/"},"wordCount":371,"publisher":{"@id":"https:\/\/ipo.org\/#organization"},"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/","url":"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/","name":"Patent Eligbility in the Life Sciences: Exergen and Praxair- and USPTO Memos on Vanda and Berkheimer - Intellectual Property Owners Association","isPartOf":{"@id":"https:\/\/ipo.org\/#website"},"datePublished":"2018-06-14T19:40:22+00:00","dateModified":"2018-07-06T19:43:10+00:00","breadcrumb":{"@id":"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ipo.org\/index.php\/patent-eligbility-life-sciences-exergen-praxair-uspto-memos-vanda-brekheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipo.org\/"},{"@type":"ListItem","position":2,"name":"Patent Eligbility in the Life Sciences: Exergen and Praxair- and USPTO Memos on Vanda and Berkheimer"}]},{"@type":"WebSite","@id":"https:\/\/ipo.org\/#website","url":"https:\/\/ipo.org\/","name":"Intellectual Property Owners Association","description":"","publisher":{"@id":"https:\/\/ipo.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipo.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ipo.org\/#organization","name":"Intellectual Property Owners Association","url":"https:\/\/ipo.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipo.org\/#\/schema\/logo\/image\/","url":"https:\/\/ipo.org\/wp-content\/uploads\/2019\/06\/ipo_logo.png","contentUrl":"https:\/\/ipo.org\/wp-content\/uploads\/2019\/06\/ipo_logo.png","width":570,"height":226,"caption":"Intellectual Property Owners Association"},"image":{"@id":"https:\/\/ipo.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/IPOAssociation\/","https:\/\/x.com\/ipo","https:\/\/www.linkedin.com\/company\/ipoassociation\/"]},{"@type":"Person","@id":"https:\/\/ipo.org\/#\/schema\/person\/8226b50acbf234bbf0f5d70f4a84ba47","name":"ipoadmin","url":"https:\/\/ipo.org\/index.php\/author\/ipoadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/23154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/comments?post=23154"}],"version-history":[{"count":1,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/23154\/revisions"}],"predecessor-version":[{"id":23155,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/23154\/revisions\/23155"}],"wp:attachment":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/media?parent=23154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/categories?post=23154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/tags?post=23154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}